8-K: HeartSciences Inc. Secures $2.8 Million in Regulation A Offering, Falling Short of $15 Million Target

HeartSciences Inc. announced it has raised $2.8 million in gross proceeds from its Regulation A offering as of July 16, 2025, significantly below its maximum target of $15 million.

Summary

• HeartSciences Inc. has completed several closings of its Regulation A Offering, raising a total of $2.8 million in gross proceeds as of July 16, 2025.
• The offering, qualified by the SEC on March 10, 2025, aimed to raise up to $15,000,000 by offering 4,285,714 units at $3.50 per unit.
• Each unit consists of one share of Series D Convertible Preferred Stock and one warrant to purchase one share of Common Stock at an exercise price of $5.00 per share.
• As a result of the closings, 797,452 units have been issued.
• Holders of 486,815 shares of Series D Preferred Stock from the issued units have elected to convert them into 486,815 shares of common stock.
• As of July 16, 2025, there were 1,797,914 shares of Common Stock issued and outstanding.

Sentiment

Score: 4

Explanation: The company successfully raised capital, which is positive, but the amount raised ($2.8 million) is significantly below the maximum target ($15 million), indicating a weaker-than-expected investor uptake for the offering.

Positives

• Successfully raised $2.8 million in gross proceeds through the Regulation A Offering.
• The offering was qualified by the SEC, indicating regulatory approval for the capital raise structure.
• The company has secured capital to support its operations and strategic initiatives.

Negatives

• The company only raised $2.8 million, which is significantly below the maximum offering amount of $15 million.
• The capital raise achieved only 18.7% of its maximum target.

Future Outlook

The document primarily reports on the completed capital raise and does not provide explicit forward-looking statements or guidance regarding future financial performance or strategic plans beyond the offering itself.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized." Andrew Simpson, President, Chief Executive Officer and Chairman of the Board of Directors.

Industry Context

This capital raise by HeartSciences Inc., a company likely operating in the healthcare technology or medical device sector given its name, is a common method for growth-stage companies to secure funding for research and development, market expansion, or general corporate purposes. Regulation A offerings allow smaller companies to raise capital from both accredited and non-accredited investors, providing an alternative to traditional public offerings or private placements.

Comparison to Industry Standards

• The document does not provide sufficient operational or financial details to allow for a specific comparison of HeartSciences Inc.'s performance or products against global industry benchmarks or specific comparable companies and projects. The focus is solely on the capital raise mechanics and results.

Stakeholder Impact

• Shareholders: Existing common shareholders may experience dilution due to the issuance of new units and the conversion of preferred stock into common stock. The capital raise provides funding for company operations, potentially benefiting long-term value.
• Investors in the Offering: New investors have acquired Series D Preferred Stock and warrants, with the potential for conversion into common stock and future gains if the stock price increases.
• Company Operations: The capital raised provides funding for the company's ongoing operations, research, and development, which could lead to new products or market expansion.

Next Steps

• The document does not explicitly mention any specific future actions, events, or milestones beyond the reporting of the completed capital raise.

Key Dates

Recommendation

Keywords

HeartSciences Inc., Regulation A Offering, SEC Filing, Capital Raise, Series D Preferred Stock, Common Stock, Warrants, Financial Reporting, Investment, Healthcare Technology, Medical Devices